These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 30987833)

  • 21. The potential prognostic value of cathepsin D protein in serous ovarian cancer.
    Chai Y; Wu W; Zhou C; Zhou J
    Arch Gynecol Obstet; 2012 Aug; 286(2):465-71. PubMed ID: 22476353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High expression of Tie-2 predicts poor prognosis in primary high grade serous ovarian cancer.
    Sopo M; Sallinen H; Hämäläinen K; Kivelä A; Ylä-Herttuala S; Kosma VM; Keski-Nisula L; Anttila M
    PLoS One; 2020; 15(11):e0241484. PubMed ID: 33151982
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HtrA1 expression and the prognosis of high-grade serous ovarian carcinoma: a cohort study using digital analysis.
    Gagné A; Têtu B; Orain M; Turcotte S; Plante M; Grégoire J; Renaud MC; Bairati I; Trudel D
    Diagn Pathol; 2018 Aug; 13(1):57. PubMed ID: 30131069
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma.
    Roy M; Connor J; Al-Niaimi A; Rose SL; Mahajan A
    Hum Pathol; 2018 Mar; 73():1-6. PubMed ID: 28851663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGF18 as a potential biomarker in serous and mucinous ovarian tumors.
    El-Gendi S; Abdelzaher E; Mostafa MF; Sheasha GA
    Tumour Biol; 2016 Mar; 37(3):3173-83. PubMed ID: 26427667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-expression of VEGF and CA9 in ovarian high-grade serous carcinoma and relationship to survival.
    Williams E; Martin S; Moss R; Durrant L; Deen S
    Virchows Arch; 2012 Jul; 461(1):33-9. PubMed ID: 22699808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential.
    Crispens MA; Bodurka D; Deavers M; Lu K; Silva EG; Gershenson DM
    Obstet Gynecol; 2002 Jan; 99(1):3-10. PubMed ID: 11777502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.
    Netinatsunthorn W; Hanprasertpong J; Dechsukhum C; Leetanaporn R; Geater A
    BMC Cancer; 2006 Apr; 6():90. PubMed ID: 16606472
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression and clinicopathologic significance of CD44v6/CD24 in ovarian serous carcinomas].
    Wang A; Lu L; Wang Y; Sun Y; Zhang Y; Guo C; Gu Y; Liu A
    Zhonghua Bing Li Xue Za Zhi; 2014 Jan; 43(1):20-4. PubMed ID: 24713244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic impact of Apaf-1, Cyclin D1, and AQP-5 in serous ovarian carcinoma treated with the first-line chemotherapy.
    Abdelrahman AE; Fathy A; Elsebai EA; Nawar N; Etman WM
    Ann Diagn Pathol; 2018 Aug; 35():27-37. PubMed ID: 30072015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and prognostic significance of APE1/Ref-1 and NPM1 proteins in high-grade ovarian serous cancer.
    Londero AP; Orsaria M; Tell G; Marzinotto S; Capodicasa V; Poletto M; Vascotto C; Sacco C; Mariuzzi L
    Am J Clin Pathol; 2014 Mar; 141(3):404-14. PubMed ID: 24515769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.
    Matsuo K; Tanabe K; Ikeda M; Shibata T; Kajiwara H; Miyazawa M; Miyazawa M; Hayashi M; Shida M; Hirasawa T; Roman LD; Mikami M
    Arch Gynecol Obstet; 2018 Mar; 297(3):749-756. PubMed ID: 29340789
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival.
    Gu Y; Li F; Qian N; Chen X; Wang H; Wang J
    J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
    Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
    Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.